Retatrutide (LY-3437943) is the most advanced investigational triple-hormone receptor agonist, representing the next generation beyond Semaglutide (GLP-1 only) and Tirzepatide (GLP-1 + GIP). This single peptide simultaneously activates three metabolic pathways, making it the leading compound for research in chronic weight management, glycemic control, and hepatic fat reduction. It is designed for metabolic syndrome research, obesity models with insulin resistance, NAFLD/NASH hepatic steatosis studies, and protocols requiring both appetite suppression and increased energy expenditure.
Retatrutide drives metabolic effects through three synergistic receptor activations in one molecule. First, GLP-1 Receptor (GLP-1R) in Pancreas: Retatrutide binds GLP-1R on pancreatic β-cells, stimulating glucose-dependent insulin secretion, delaying gastric emptying to increase satiety, and suppressing glucagon release to lower blood glucose, resulting in improved glucose control. Second, GIP Receptor (GIPR) in Brain Hypothalamus: Activates hypothalamic appetite centers, promotes satiety signals to suppress appetite and reduce food intake, and enhances lipid clearance and fatty acid oxidation. Third, Glucagon Receptor (GCGR) in Liver: Increases energy expenditure and thermogenesis, stimulates lipolysis and fatty acid oxidation, and promotes hepatic fat clearance and glycogenolysis, resulting in higher calorie burn and reduced liver fat. The integrated outcome is insulin secretion ↑, appetite & satiety ↓, energy expenditure ↑, liver health ↑, with research showing up to ∼24% body weight loss, HbA1c reduction ∼2.0%, and hepatic fat reduction of -82% in studies.
Our Retatrutide lineup is supplied as high-purity lyophilized powder (>99% HPLC) with COA and batch testing. For dose-escalation research, we offer Retatrutide 5mg (starter protocol), Ret 10mg (most requested standard), Ret 15mg (intermediate), Retatrutide 20mg (high-dose) and Retatrutide 30mg (value size for long-term protocols). All models are unimolecular triple agonists (GLP-1 + GIP + Glucagon), stable for 24 months at -20°C and 30 days reconstituted at 2-8°C. Compared to dual agonists, Retatrutide uniquely adds glucagon-driven energy expenditure to the GLP-1/GIP appetite suppression, making it the most comprehensive model for metabolic rate, fat loss, and liver metabolism research. For Research Use Only, not for human consumption.